Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Claudin-18.2

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

Kleemann joins Merck from Boehringer

Appointed head of group tax

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Roche - Basel

EU backs Roche’s Kadcyla in breast cancer

Green light for Herceptin follow-up

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

- PMLiVE

Late-stage ovarian cancer

Novel treatment strategies have yielded several promising agents that have reached phase III

- PMLiVE

Priority review for Lilly’s ramucirumab in gastric cancer

Update comes as company posts improved revenue results

- PMLiVE

Public unaware of main cause of liver cancer

Janssen-backed survey finds one in six people is aware of viral hepatitis role in the disease

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

Kidney cancer campaign launches in UK

The ‘Be Clear on Cancer’ campaign is aimed at raising awareness of the symptoms of bladder and kidney cancers

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links